Rostock, 2024 May 02 SensID GmbH, a leading provider of quality assurance materials for the diagnostic industry, proudly announces the launch of its groundbreaking metagenome control material. This innovative solution promises to revolutionize molecular healthcare through the rapid identification of thousands of microbes.
Traditional diagnostic methods often take precious time to identify a limited number of pathogens. In contrast, SensID’s new metagenome control material enables the detection of bacteria, DNA viruses, fungi and parasites within a single day using next-generation sequencing (NGS) and polymerase chain reaction (PCR) platforms.
“Our goal at SensID is to transform molecular diagnostics and improve healthcare worldwide,” said Björn Nowack, CEO of SensID. “Our new metagenome control material is a milestone on this journey as it significantly improves the accuracy and efficiency of diagnosing life-threatening diseases such as sepsis, cancer and endocarditis.”
SensID’s metagenome control material provides clinical laboratories with an indispensable resource to ensure the validation and regular verification of state-of-the-art diagnostic technologies. By rapidly identifying potential pathogens, this solution helps to optimize patient care and provide life-saving treatments.

For more information, please visit our website or contact us at

About SensID GmbH:

SensID GmbH is a leading provider of quality control materials for the diagnostic industry. With a commitment to innovation and precision, SensID ensures the accuracy and reliability of diagnostic testing, ultimately contributing to better patient care.

For media inquiries, please contact:

Jens Beator